Last checked at 15 Dec 2023 17:14
London stocks log weekly gains as cenbank fest ends
FTSE 100 down 1.0%, FTSE 250 off -0.3%
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat1
AZN Share
Trades2,050
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,388.00
Bid:
12,388.00
Ask:
12,392.00
Change:
56.00 (0.45%)
Spread:
4.00 (0.032%)
Open:
12,350.00
High:
12,390.00
Low:
12,314.00
Prev. Close:
12,332.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca's Imfinzi fails to reach endpoint in difficult trial
Fri, 07th Dec 2018 07:24
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced overall survival results for the Phase III EAGLE trial of Imfinzi (durvalumab) on Friday.The FTSE 100 pharmaceutical behemoth described EAGLE as a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab - an anti-CTLA4 antibody - compared to standard-of-care chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.It said Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival compared to standard-of-care chemotherapy in the "hard-to-treat" patients.The safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous experience."The prognosis for recurrent or metastatic head and neck squamous cell cancer is very poor and new treatments for this group of cancers are urgently needed," said AstraZeneca's executive vice-president of global medicines development and chief medical officer Sean Bohen."While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer."We look forward to seeing the results of the Phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019."AstraZeneca said it would submit the results from the Phase III EAGLE trial for presentation at a forthcoming medical meeting.
More News
15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more13 Dec 2023 17:07
UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision
UK economy shrinks by 0.3% in October
*Read more12 Dec 2023 16:00
London close: Stocks slip as investors digest US inflation
(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.
Read more12 Dec 2023 12:07
London midday: FTSE still firmer ahead of US inflation print
(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:53
LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI
(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.
Read more12 Dec 2023 08:37
AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion
(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:16
AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.
Read more12 Dec 2023 02:00
UK companies pause China investment decisions as economy slows, survey shows
BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.
Read more11 Dec 2023 08:15
AstraZeneca says danicopan tests well as blood disorder treatment
(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more1 Dec 2023 08:52
LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI
(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.
Read more